PMID- 38528688
OWN - NLM
STAT- Publisher
LR  - 20240326
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
DP  - 2024 Mar 25
TI  - Soy-derived isoflavones as chemo-preventive agents targeting multiple signalling 
      pathways for cancer prevention and therapy.
LID - 10.1111/bph.16353 [doi]
AB  - The chemopreventive and chemotherapeutic properties of soy and soy-derived 
      compounds, especially isoflavones, have been extensively studied in recent years. 
      However, in contrast to their anticancer effects, such as cell growth inhibition, 
      cell cycle arrest and apoptosis induction, isoflavones have also been found to 
      promote the growth of cancer cells. Therefore, the aim of this comprehensive 
      review article is to present the current state of knowledge regarding the 
      molecular mechanisms by which soy-derived isoflavones target multiple cellular 
      signalling pathways in cancer cells. Our findings indicate that soy-derived 
      isoflavones act as, among other things, potent modulators of HOX transcript 
      antisense RNA (HOTAIR)/SWI/SNF-related matrix-associated actin-dependent 
      regulator of chromatin subfamily B member 1 (SMARCB1), vascular endothelial 
      growth factor (VEGF)/C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif 
      chemokine receptor type 4 (CXCR4), 17-beta-oestradiol (E2)/oestrogen receptor-alpha 
      (ERalpha)/neuroglobin (NGB) and sonic hedgehog signalling pathways, epigenetic 
      modulatory agents (i.a. miR-155, miR-34a and miR-10a-5p) and cancer stem cells 
      and epithelial-to-mesenchymal transition inhibitors. The paper also discusses the 
      latest epidemiological studies and clinical trials and provides an insight into 
      recent extensive research on the chemo-preventive and therapeutic potential of 
      soy-derived isoflavones.
CI  - (c) 2024 British Pharmacological Society.
FAU - Kaufman-Szymczyk, Agnieszka
AU  - Kaufman-Szymczyk A
AD  - Department of Biomedical Chemistry, Faculty of Health Sciences, Medical 
      University of Lodz, Lodz, Poland.
FAU - Jalmuzna, Justyna
AU  - Jalmuzna J
AD  - Department of Biomedical Chemistry, Faculty of Health Sciences, Medical 
      University of Lodz, Lodz, Poland.
FAU - Lubecka-Gajewska, Katarzyna
AU  - Lubecka-Gajewska K
AD  - Department of Biomedical Chemistry, Faculty of Health Sciences, Medical 
      University of Lodz, Lodz, Poland.
LA  - eng
GR  - 503/6-099-01/503-61-001/Uniwersytet Medyczny w Lodzi/
PT  - Journal Article
PT  - Review
DEP - 20240325
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
SB  - IM
OTO - NOTNLM
OT  - anticancer
OT  - cancer
OT  - daidzein
OT  - equol
OT  - genistein
OT  - glycitein
OT  - isoflavones
OT  - molecular mechanisms
OT  - prevention
OT  - signalling pathways
OT  - soy
OT  - treatment
EDAT- 2024/03/26 06:45
MHDA- 2024/03/26 06:45
CRDT- 2024/03/26 01:43
PHST- 2024/01/19 00:00 [revised]
PHST- 2023/08/07 00:00 [received]
PHST- 2024/02/08 00:00 [accepted]
PHST- 2024/03/26 06:45 [medline]
PHST- 2024/03/26 06:45 [pubmed]
PHST- 2024/03/26 01:43 [entrez]
AID - 10.1111/bph.16353 [doi]
PST - aheadofprint
SO  - Br J Pharmacol. 2024 Mar 25. doi: 10.1111/bph.16353.